BCL2 and B-cell non-Hodgkin lymphoma: Equal to venetoclax, the BCL-2 inhibitor ABT-737 (Figure 2) was found to potentiate CAR-T-cell cytotoxicity against selected B-cell lymphoma cell lines resistant to apoptosis, underscoring the advantage of combinatorial targeting of CAR-T cells and small molecules [34].